Palliative (and non-palliative) radiation therapy in late-stage prostate cancer today

The role of radiation therapy in the management of men with advanced (i.e., metastatic and castration-resistant) forms of prostate cancer has been evolving over the past 5 years or so. … READ MORE …

When is radiopharmaceutical therapy most appropriately initiated in men with mCRPC?

A newly published paper by a team of Italian researchers has added a wrinkle to the critical questions about the most effective current and future forms of sequential therapy for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Single- vs. multi-fraction radiation therapy for metastatic, bone-related cancer pain

Data published in 2005 and later have clearly shown that — for most patients — single-fraction radiation therapy (e.g., a single dose of 8 Gy) is better than multi-fraction radiation therapy (e.g., 30 Gy given over 10 treatments) for the treatment of bone pain consequent to metastatic cancer that has spread into the bones (in prostate cancer and other forms of cancer). … READ MORE …

ASCO issues guidance on end-of-life care for cancer patients

The idea that having good policies and procedures in place to help patients and family members to address end-of-life care is highly controversial in some quarters. However, The “New” Prostate Cancer InfoLink believes that there is a great need for clear professional and consumer guidance on end-of-life care related to cancer … … READ MORE …

The right way to deliver palliative radiation therapy for pain management

It has come to our attention that the American Society for Radiation Oncology (ASTRO) has developed new guidance on the use of palliative external beam radiation therapy (EBRT) for the management of pain associated with metastasis of cancer to bone — a relatively common problem in late stage, metastatic prostate cancer. … READ MORE …

Palliative prostate-specific radiotherapy in men with advanced prostate cancer

It is still not unusual, in large parts of the world, for patients to be diagnosed with prostate cancer and treated with hormone therapy as a first-line treatment or following a period of active surveillance or monitoring — for all sorts of reasons. … READ MORE …